BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CDP7851: Phase II data

Top-line data from a double-blind, international Phase II trial in about 400 postmenopausal women with low BMD showed that subcutaneous AMG 785 met the primary endpoint of significantly increasing lumbar spine BMD from baseline to 12 months vs. placebo. The partners also said that AMG 785 compared...

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >